Instrument Inactif

Communiqués Impax Laboratories Inc Nasdaq

Actions

US45256B1017

Produits pharmaceutiques

Communiqués

17/08	Amneal Completes Acquisition Of Kashiv	AQ
10/08	Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader	GL
10/08	Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader	AQ
30/07	Amneal: Q2 Earnings Snapshot	AQ
30/07	Amneal Reports Second Quarter 2026 Financial Results	GL
17/07	Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations	GL
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026	GL
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026	AQ
08/07	Amneal Pharmaceuticals : and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector	PU
01/07	Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program	PU
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations	GL
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations	AQ
10/06	Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals	PR
08/06	Amneal And Kashiv File IPR Petition On Omalizumab Patent	AQ
05/06	Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease	GL
04/06	Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution	GL
01/06	Amneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026	GL
11/05	Amneal Agrees To Acquire Kashiv BioSciences For Total Payment Up To $1.1 Billion	AQ
08/05	Amneal Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Amneal Reports First Quarter 2026 Financial Results	GL
22/04	Amneal Pharmaceuticals : Kashiv Biosciences Acquisition and Q1 2026 Financial Results	PU
22/04	Amneal: Q1 Earnings Snapshot	AQ
22/04	Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader	BU
22/04	Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance	GL
20/04	Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®	GL